Product image of Itam (Sitagliptin) supplied by GNH India

Itam

Active Ingredient:
Sitagliptin
Origin:
EU

Itam (Sitagliptin)

Sitagliptin, the active ingredient in Itam, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycemic control when used in combination with diet and exercise.

GNH India supplies Itam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets. The company adheres to stringent manufacturing standards and provides reliable logistics for timely delivery.

Manufacturer / TM Owner

Lifewell - Pharmaceutical & Healthcare, Lda.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Sitagliptin is used in the treatment of type 2 diabetes, a chronic metabolic disorder characterized by elevated blood glucose.

  • Type 2 diabetes mellitus: lowers fasting plasma glucose and HbA1c levels when combined with diet and exercise.
  • Type 2 diabetes mellitus (as add‑on therapy): provides additional glycemic reduction when combined with other antidiabetic agents such as metformin.
  • Type 2 diabetes mellitus (monotherapy): can be used alone to achieve target glucose control in patients intolerant to other agents.

How It Works

  • Sitagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, which degrades the incretin hormones glucagon‑like peptide‑1 (GLP‑1) and glucose‑dependent insulinotropic polypeptide (GIP). By blocking DPP‑4, sitagliptin increases circulating levels of GLP‑1 and GIP, enhancing glucose‑dependent insulin secretion and suppressing glucagon release, thereby improving post‑prandial and overall glycemic control without causing hypoglycemia in the absence of other agents.

Side Effects

Sitagliptin may cause adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Nausea
  • Headache
  • Upper respiratory tract infection
  • Nasopharyngitis
  • Diarrhea
  • Arthralgia

Serious or Rare Side Effects

  • Acute pancreatitis
  • Severe allergic reactions (anaphylaxis)
  • Bullous skin disorders
  • Hepatic injury
  • Severe joint pain
  • Angioedema or hypersensitivity reactions

Precautions & Warnings

Before initiating therapy, clinicians should consider several safety aspects.

  • Renal impairment: dose adjustment may be required based on renal function.
  • Hepatic impairment: use with caution in patients with liver disease.
  • Hypersensitivity: discontinue if signs of allergic reaction appear.
  • Pancreatitis risk: monitor for persistent abdominal pain.
  • Cardiovascular disease: no specific contraindication but monitor in patients with heart disease.
  • Store at room temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Sitagliptin can interact with other medicines, requiring attention to the level of interaction.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce sitagliptin exposure.
  • Concurrent use of another DPP‑4 inhibitor: duplicate therapy should be avoided.
  • Co‑administration with potent diuretics in dehydrated patients: may increase risk of renal impairment.

Moderate Interactions (Monitor Closely)

  • Metformin: monitor renal function to reduce risk of lactic acidosis.
  • ACE inhibitors or ARBs: observe renal parameters when combined.
  • Warfarin: periodic INR checks are advisable as sitagliptin may affect anticoagulation control.

Frequently Asked Questions

Itam contains sitagliptin, which is prescribed for the management of type 2 diabetes mellitus. It helps lower elevated blood glucose levels by improving the body’s own insulin response when used together with diet and exercise.

Sitagliptin works by selectively inhibiting the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition raises the levels of the incretin hormones GLP‑1 and GIP, which increase insulin secretion and reduce glucagon release in a glucose‑dependent manner, leading to better overall glycemic control.

The appropriate dose of Itam is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Limited clinical data are available for sitagliptin use in pregnancy and lactation. Because safety has not been established, it is generally advised to avoid Itam during pregnancy and breastfeeding unless the potential benefit justifies the potential risk, as assessed by a qualified clinician.

To request Itam, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Itam (sitagliptin) belongs to the DPP‑4 inhibitor class, offering glucose‑dependent insulin secretion with a low risk of hypoglycemia compared with sulfonylureas. Unlike insulin, it is an oral agent, and unlike metformin, it does not typically cause gastrointestinal upset, making it a useful alternative or add‑on therapy.

Itam should be stored at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain product stability throughout its shelf life.

Itam is taken orally as a tablet with a glass of water. It can be taken with or without food, and the dose is usually taken once daily as directed by the prescriber.

The most serious adverse events linked to sitagliptin include acute pancreatitis, severe allergic reactions such as anaphylaxis, and rare skin disorders like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or signs of an allergic reaction.

Itam should be avoided in individuals with a known hypersensitivity to sitagliptin or any component of the formulation. Caution is also advised for patients with severe renal impairment, as dose adjustment may be required, and for those with a history of pancreatitis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT